Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06857851 · ClinicalTrials.gov registry record
Optimizing Deep Brain Stimulation to Improve Visuomotor Function in Parkinson's Disease
A clinical trial, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- 80
- Enrollment target
NCT06857851: Recruiting study, sponsored by VA Office of Research and Development.
NCT06857851 is a clinical trial that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06857851 is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- 80 participants
- Enrollment target
Study Summary
Inability to align and refocus the eyes on the objects at different depths, i.e., vergence impairment and strabismus, frequently affects the quality of life in patients with Parkinson's disease. The investigators study aims to understand the location-specific effects of subthalamic region deep brain stimulation on vergence and strabismus by integrating the patient-specific deep brain stimulation models and high-resolution eye-tracking measures. The knowledge gained will allow the investigators to find the most beneficial stimulation location and parameters for improving binocular coordination, strabismus, and vergence while preserving the ability to treat motor symptoms in Parkinson's disease.
Primary Outcome
The investigators will measure vergence gain as one outcome measure. This measure will be calculated by measuring ratio of observed versus expected difference between the horizontal angular positions of the right and left eye as participants move gaze from far to near or vice versa.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2029-10-01 |
What NCT06857851 shows while recruiting
NCT06857851 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT06857851 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06857851 about?
NCT06857851 is a clinical study titled "Optimizing Deep Brain Stimulation to Improve Visuomotor Function in Parkinson's Disease". Inability to align and refocus the eyes on the objects at different depths, i.e., vergence impairment and strabismus, frequently affects the quality of life in patients with Parkinson's disease. The investigators study aims to understand the location-specific effects of subthalamic region deep brain...
What is the current status of trial NCT06857851?
This trial is currently recruiting. The enrollment target is 80 participants. The study started on 2026-02-01. Estimated completion is 2029-10-01.
Who is sponsoring clinical trial NCT06857851?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI